Tools and Methods for Producing High Quality Functional Protein Microarrays for Biomarker Discovery

Information

  • Research Project
  • 9767874
  • ApplicationId
    9767874
  • Core Project Number
    R43OD024970
  • Full Project Number
    5R43OD024970-02
  • Serial Number
    024970
  • FOA Number
    PA-15-052
  • Sub Project Id
  • Project Start Date
    9/1/2018 - 5 years ago
  • Project End Date
    8/31/2020 - 3 years ago
  • Program Officer Name
    VONKOLLMAR, DESIREE
  • Budget Start Date
    9/1/2019 - 4 years ago
  • Budget End Date
    8/31/2020 - 3 years ago
  • Fiscal Year
    2019
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/22/2019 - 4 years ago
Organizations

Tools and Methods for Producing High Quality Functional Protein Microarrays for Biomarker Discovery

Abstract: Functional protein microarrays find applications in high throughput disease biomarker discovery, understanding the incidence and role of post translational modifications (PTMs) in disease pathology, investigating activity and function of enzymes, protein?protein and protein? small molecule interactions, among others. Nucleic Acid Programmable Protein Array (NAPPA) technology is a robust method for producing cell-free in situ expressed functional protein microarrays in human lysate, freshly expressed and displayed at the time of assay, and has been widely applied in disease biomarker discovery research over the last decade. We aim to develop an advanced instrument for automating the production of NAPPA IPC (Isolated Protein Capture) high density protein microarrays on glass slides. Once the instrument is developed, we expect similar improvements in simplicity, speed and quality of NAPPA protein microarray assays as was seen when DNA microarrays were transferred from manual to automated workstations. In addition to clinical biomarker research, it is an ideal platform for profiling for disease biomarkers in animal models, a subset of which can then be monitored as prognostic biomarkers, indicators of end points in drug development pre-clinical trials.

IC Name
OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH
  • Activity
    R43
  • Administering IC
    OD
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    349552
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    350
  • Ed Inst. Type
  • Funding ICs
    OD:349552\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INANOBIO, INC.
  • Organization Department
  • Organization DUNS
    079962474
  • Organization City
    TEMPE
  • Organization State
    AZ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    852841034
  • Organization District
    UNITED STATES